default author photo

Travis T. Sims

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

2

DOWNLOADS

66

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Oral cyclophosphamide combined with bevacizumab in recurrent heavily pretreated ovarian cancer

Number of pages: 22 Posted: 06 Nov 2025
Mostafa F. Eyada, Victoria Michael, Shrina Patel, Jeffrey Andrew How, Roni Nitecki Wilke, Amir A. Jazaeri, Nicole D. Fleming, Pamela Soliman, Anil Sood, Shannon N. Westin and Travis T. Sims
affiliation not provided to SSRN, McGovern Medical School at UTHealth, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and affiliation not provided to SSRN
Downloads 47 (1,170,409)

Abstract:

Loading...

Recurrent ovarian cancer, High-grade serous ovarian cancer (HGSOC), Platinum resistant ovarian cancer (PROC), Cyclophosphamide, Bevacizumab.

2.

Complete Response to Trastuzumab-Deruxtecan (Enhertu, T-Dxd) in Her2-Positive Stage Ivb Uterine Carcinosarcoma

Number of pages: 8 Posted: 16 May 2025
Michael Kim, Amma Asare, Jamie L. Dockery, Nadia Hameed and Travis T. Sims
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 19 (1,459,862)

Abstract:

Loading...

Trastuzumab-deruxtecan, Enhertu, T-DXd, uterine carcinosarcoma, HER2, NED